Cited by 495Angiogenesis and VEGF in CancerConnective Tissue Growth Factor ResearchCancer Mechanisms and Therapy

CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth

Open access
Babic, Alexander M., Kireeva, Maria L., Kolesnikova, Tatiana V., Lau, Lester F.·1998·Proceedings of the National Academy of Sciences

Abstract

CYR61 is a secreted, cysteine-rich, heparin-binding protein encoded by a growth factor-inducible immediate–early gene. Acting as an extracellular, matrix-associated signaling molecule, CYR61 promotes the adhesion of endothelial cells through interaction with the integrin α V β 3 and augments growth factor-induced DNA synthesis in the same cell type. In this study, we show that purified CYR61 stimulates directed migration of human microvascular endothelial cells in culture through an α V β 3 -dependent pathway and induces neovascularization in rat corneas. Both the chemotactic and angiogenic activities of CYR61 can be blocked by specific anti-CYR61 antibodies. Whereas most human tumor-derived cell lines tested express CYR61 , the gastric adenocarcinoma cell line RF-1 does not. Expression of the CYR61 cDNA under the regulation of a constitutive promoter in RF-1 cells significantly enhances the tumorigenicity of these cells as measured by growth in immunodeficient mice, resulting in tumors that are larger and more vascularized than those produced by control RF-1 cells. Taken together, these results identify CYR61 as an angiogenic inducer that can promote tumor growth and vascularization; the results also suggest potential roles for CYR61 in physiologic and pathologic neovascularization.

Integrity signals

Registry

Crossref · 10.1073/pnas.95.11.6355

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • CCN1 has potent angiogenic activity, first demonstrated in a corneal micropocket implant assay and confirmed in a rabbit ischemic hindlimb model.

    “Indeed, CCN1 has potent angiogenic activity, first demonstrated in a corneal micropocket implant assay [83] and subsequently confirmed in a rabbit ischemic hindlimb model [84].”

    From CCN1/CYR61: the very model of a modern matricellular protein (2011) · cites this paper as [83]

  • CCN1 promotes tumor growth and increases tumor vascularization when overexpressed in human gastric adenocarcinoma cells in SCID mice.

    “With the discovery of its angiogenic activity, CCN1 was shown to promote tumor growth and increase tumor vascularization when overexpressed in human gastric adenocarcinoma cells in SCID mice [83].”

    From CCN1/CYR61: the very model of a modern matricellular protein (2011) · cites this paper as [83]

  • CCN1 can promote growth of tumors generated by transformed cells, typically in xenografts transplanted into immunodeficient mice.

    “These findings demonstrated the ability of CCN1 to promote the growth of tumors generated by transformed cells, typically observed in xenografts transplanted into immunodeficient mice.”

    From CCN1/CYR61: the very model of a modern matricellular protein (2011) · cites this paper as [83]

  • CCN1 is a powerful angiogenic inducer in vivo.

    “First, CCN1 is a powerful angiogenic inducer in vivo [72,83], and angiogenesis is essential for the supply of oxygen and nutrients to nourish the growing tumor [140].”

    From CCN1/CYR61: the very model of a modern matricellular protein (2011) · cites this paper as [83]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Babic, A. M., Kireeva, M. L., Kolesnikova, T. V., & Lau, L. F.
Affiliations
University of Illinois Chicago (US)
Corresponding author
Lau, Lester F.
Venue
Proceedings of the National Academy of Sciences
Published
1998-05-26
Volume
95
Issue
11
Pages
6355-6360
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2032912914
Cited by
495
References
53
Citations by year
2026: 4 · 2025: 9 · 2024: 15 · 2023: 11 · 2022: 9 · 2021: 26 · 2020: 11 · 2019: 13 · 2018: 8 · 2017: 11 · 2016: 20 · 2015: 19 · 2014: 22 · 2013: 15 · 2012: 19
FWCI
6.28
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (R01CA046565, CA-46565)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Connective Tissue Growth Factor Research
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Cancer Mechanisms and Therapy
Keywords
CYR61, angiogenesis, tumor growth, immediate early genes, heparin-binding protein, integrin αvβ3, endothelial cell migration, endothelial cell adhesion, neovascularization, cornea, tumor vascularization, gastric adenocarcinoma, tumorigenicity, chemotaxis
MeSH terms
Animals, Cell Division, Cell Movement, Chemotaxis, Endothelium, Vascular, Growth Substances, Humans, Mice, Nude, Neoplasms, Experimental, Neovascularization, Pathologic, Tumor Cells, Cultured, Immediate-Early Proteins, Intercellular Signaling Peptides and Proteins, Mice, Rats, Cysteine-Rich Protein 61

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review